Analyst Price Targets — ALGS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 21, 2026 10:32 am | — | Cantor Fitzgerald | $20.00 | $5.60 | TheFly | Aligos Therapeutics initiated with an Overweight at Cantor Fitzgerald |
| January 7, 2026 5:38 am | Michael Yee | UBS | $20.00 | $8.76 | StreetInsider | UBS Starts Aligos Therapeutics Inc. (ALGS) at Buy |
| January 6, 2023 9:01 am | — | Piper Sandler | $3.00 | $1.22 | Benzinga | Piper Sandler Upgrades Aligos Therapeutics to Overweight, Raises Price Target to $3 |
| January 6, 2023 5:24 am | — | Jefferies | $3.00 | $0.99 | Benzinga | Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3 |
Latest News for ALGS
SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has completed enrollment of both the HBeAg+ (Part 1a) and HBeAg- (Part 2a) participants in the Phase 2 B-SUPREME study of pevifoscorvir…
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license…
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilur
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) today announced that pivotal Phase 2 results from the PROGRESS study evaluating zilurgiser
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced new data from its rare liver disease programs. Late-breaking result
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALGS.
U.S. House Trading
No House trades found for ALGS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.